[Current drug treatment of hepatitis C : Useful therapy algorithms taking into consideration economical aspects].

Der Internist
K DeterdingH Wedemeyer

Abstract

Treatment of chronic hepatitis C (HCV) has changed dramatically since the approval of the direct-acting antivirals (DAA). Depending on the HCV genotype and the stage of liver disease, sustained HCV clearance can be achieved in more than 95% of patients with a treatment duration of 8-12 weeks in most of the cases. The selection and combination of the drugs depends on previous antivirals therapies, the stage of liver fibrosis, HCV genotype and subtype, viral load at baseline, and renal function. Nowadays, potent antiviral therapy with minimal side effects can be offered to almost every patient. In the real-world setting, a high quality of HCV therapy considering economic aspects has been documented in the German Hepatitis C Registry. A reduction of clinical complications of chronic liver disease by clearance of HCV has already been documented.

References

Jan 17, 2002·The New England Journal of Medicine·E JaeckelUNKNOWN German Acute Hepatitis C Therapy Group
Jul 10, 2003·Gastroenterology·J Tilman GerlachGerd R Pape
Oct 21, 2005·Journal of Hepatology·Manfred WieseUNKNOWN East German Hepatitis C Study Group
Sep 9, 2008·The Journal of Antimicrobial Chemotherapy·Johannes WiegandHeiner Wedemeyer
Sep 29, 2009·Gastroenterology·Gregory J DoreUNKNOWN Australian Trial In Acute Hepatitis C Study Group
May 1, 2012·The Lancet Infectious Diseases·Jason GrebelyUNKNOWN International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3)
Mar 26, 2013·The Lancet Infectious Diseases·Katja DeterdingUNKNOWN Hep-Net Acute HCV-III Study Group
Apr 15, 2014·The New England Journal of Medicine·Nezam AfdhalUNKNOWN ION-2 Investigators
Apr 4, 2015·Lancet·Heiner Wedemeyer
May 20, 2015·Gastroenterology·Michael CharltonUNKNOWN SOLAR-1 Investigators
Nov 17, 2015·The New England Journal of Medicine·Michael P CurryUNKNOWN ASTRAL-4 Investigators
Nov 17, 2015·The New England Journal of Medicine·Jordan J FeldUNKNOWN ASTRAL-1 Investigators
Nov 18, 2015·The New England Journal of Medicine·Graham R FosterUNKNOWN ASTRAL-3 Investigators
Nov 28, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Christoph Höner Zu SiederdissenHeiner Wedemeyer
Jan 4, 2017·PloS One·Jona T StahmeyerChristian Krauth
Jan 13, 2017·Alimentary Pharmacology & Therapeutics·M CornbergC Niederau
Apr 14, 2017·The Lancet. Gastroenterology & Hepatology·UNKNOWN Polaris Observatory HCV Collaborators
Jun 1, 2017·The New England Journal of Medicine·Marc BourlièreUNKNOWN POLARIS-1 and POLARIS-4 Investigators
Sep 20, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·David WylesFederico J Mensa
Sep 30, 2017·Liver International : Official Journal of the International Association for the Study of the Liver·Christoph Höner Zu SiederdissenKatja Deterding
Oct 12, 2017·The New England Journal of Medicine·Edward GaneFederico J Mensa
Nov 15, 2017·Journal of Hepatology·Peter BuggischStefan Zeuzem
Mar 8, 2018·United European Gastroenterology Journal·Christoph Höner Zu SiederdissenStefan Mauss

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

The Lancet Infectious Diseases
Stelliana GoutzamanisPeter Higgs
Journal of Clinical Gastroenterology
Francis Dailey, Walid S Ayoub
© 2022 Meta ULC. All rights reserved